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BACKGROUND: Recent multisite trials reveal striking heterogeneities 
in results between trial sites. These may be because of population 
differences indicating different treatment benefits among different 
types of participants or site anomalies, such as failures to adhere to 
study protocols that could negatively affect study validity. We sought 
to determine whether a new data analysis strategy—transportability 
methods—could suggest site anomalies not readily identified through 
standard methods.
METHODS AND RESULTS: We applied transportability methods to 2 
large, multicenter cardiovascular disease treatment trials: the TOPCAT 
trial (Treatment of Preserved Cardiac Function Heart Failure With an 
Aldosterone Antagonist; n=3445) comparing spironolactone to placebo for 
heart failure (for which site anomalies were suspected) and the ACCORD 
BP trial (Action to Control Cardiovascular Risk in Diabetes–Blood Pressure; 
n=4733) comparing intensive-to-standard blood pressure treatment (for 
which site anomalies were not suspected). The transportability methods 
give expected results by standardizing from one site to another using 
data on participant covariates. The difference between the expected 
and observed results was assessed using calibration tests to identify 
whether treatment-effect differences between sites could be explained by 
participant population characteristics. Standard regression methods did 
not detect heterogeneities in TOPCAT between Russia/Georgia study sites 
suspected of study protocol violations and sites in the Americas (P=0.12 
for difference in primary cardiovascular outcome; P=0.20 for difference 
in total mortality). The transportability methods, however, detected 
the difference between Russia/Georgia sites and sites in the Americas 
(P<0.001) and found that measured participant characteristics did not 
explain the between-site discrepancies. The transport methods found no 
such discrepancies between sites in ACCORD BP, suggesting participant 
characteristics explained between-site differences.
CONCLUSIONS: Transportability methods may be superior to standard 
approaches for detecting anomalies within multicenter randomized 
trials and assist data monitoring boards to determine whether important 
treatment-effect heterogeneities can be attributed to participant 
differences or potentially to site performance differences requiring further 
investigation.
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Multisite trials that include international popula-tions are an important method to rigorously e-valuate clinical treatment strategies. However, 
it can be difficult for central data monitoring boards to 
ensure the quality of large, multicenter trials,1 and the 
trials can be subject to heterogeneity across sites. This 
heterogeneity may be because of differences in how 
different populations benefit from the study interven-
tion (an important scientific finding) or may be because 
of differences in how sites execute the trial protocol.2–6 
These execution differences may be legitimate variation 
in interpretation or implementation of the protocol or, 
of concern, represent fraudulent data generation and 
improper intervention delivery to participants.3–5
At present, the most common approach for monitor-
ing heterogeneity in site-specific results is to statistically 
estimate site-by-treatment group interaction terms in 
a regression model, to determine whether the average 
treatment effect estimated at a given site differs from 
the average treatment effect estimated from the trial 
as a whole. But such an approach may have insuffi-
cient power to detect meaningful differences and does 
not clarify whether differences in characteristics of the 
participants from that site can explain any between-site 
heterogeneity that is detected. Recent methodological 
innovations known as transportability methods may 
offer improvements over this standard approach.7–10
To help understand the need for transportability 
methods, we first note that the average treatment 
effect in one setting, estimated by a randomized clini-
cal trial, is the difference (or ratio, depending on effect 
type) in outcomes comparing treated to untreated par-
ticipants. Thus, it is specific to the particular distribu-
tion of potential effect modifiers and prognostic factors 
(eg, age, sex, race/ethnicity, or geographic location), of 
those included in the trial. However, the sample partici-
pating in a trial may be distinct from the population we 
are trying to understand. This can raise questions about 
the generalizability or transportability of the findings. 
Transportability methods utilize understanding of the 
differences between populations and the conditions 
that license the extrapolation of causal effects to the 
population we are trying to understand. For example, 
we can use transportability methods to model the rela-
tionship between relevant covariates and a given treat-
ment-outcome relationship in a particular setting (the 
source site) and then use those models to project what 
the outcome would be were the treatment applied 
to a setting with a different distribution of covariates 
(the target site). Hence, the methods seek to transport 
estimates of treatment effects from one setting to an-
other. Such estimates can be useful if we wish to apply 
results from a clinical trial to a population with a dif-
ferent distribution of covariates. In addition, the trans-
ported estimates may allow one to determine whether 
results from certain sites within a multisite trial differ 
more than would be expected from results at other sites 
within the trial.
In this study, we used transportability methods 
to identify whether they could detect potential site 
anomalies in the TOPCAT trial (Treatment of Preserved 
Cardiac Function Heart Failure With an Aldosterone 
Antagonist). TOPCAT was an NIH-sponsored study 
of spironolactone therapy in individuals with heart 
failure with preserved ejection fraction.2 Although 
the study did not find that spironolactone reduced 
the occurrence of the primary outcome, subsequent 
investigations suggested there were abnormalities 
when comparing sites in Russia/Georgia and sites in 
the Americas. We additionally sought to determine 
whether the transportability methods would be overly 
sensitive (and trigger false-positive warnings) about 
site variability by applying transportability methods to 
a trial for which site differences were not anticipated 
to explain effect size heterogeneity (ACCORD BP trial 
[Action to Control Cardiovascular Risk in Diabetes–
Blood Pressure] of intensive versus standard blood 
pressure treatment).11
METHODS
Data Source and Description
Data for this study came from the public release individual 
participant data files f or t he T OPCAT a nd A CCORD B P t ri-
als, available from the Biologic Specimen and Data Repository 
Information Coordinating Center of the National Heart, Lung, 
and Blood Institute. The TOPCAT study was a randomized, 
multisite, clinical trial comparing the use of spironolactone 
versus placebo in individuals with a history of heart failure 
with preserved ejection fraction. Individuals >50 years of age 
were eligible if they reported at least 1 sign and 1 symptom 
of heart failure, had a left ventricular ejection fraction >45%, 
controlled systolic blood pressure, and serum potassium <5.0 
mmol/L. Further, eligible patients were required to have had a 
hospitalization for heart failure within the last 12 months or 
an elevated BNP (brain natriuretic peptide) or N-terminal pro-
BNP level (or both).2 Exclusion criteria were limited life expec-
tancy, severe renal dysfunction, and other comorbidities.2 The 
median study follow-up time for the primary outcome was 
3.0 years.2 A full study protocol and primary and secondary 
results have been published. Sites within TOPCAT were 
located in the United States, Canada, Argentina, and Brazil 
(the Americas) and in Russia and the Republic of Georgia. 
The primary result of the TOPCAT trial was that spironolac-
tone was not superior to placebo, but subsequent analyses 
found that spironolactone metabolite was more often absent 
from individuals who reported taking spironolactone enrolled 
at Russian sites, compared with study sites in the Americas 
(≈30% versus ≈3%).4 Further, spironolactone did not produce 
a significant reduction in the risk of the primary outcome 
among patients in the Russia/Georgia sites but did produce a 
significant reduction elsewhere (hazard ratio, 1.10; 95% CI, 
0.79–1.51 in Russia/Georgia, versus hazard ratio, 0.82; 95% 
CI, 0.69–0.98 elsewhere).3 Despite this, the site-by-treatment 
interaction tested was not significant.3
ACCORD BP was a randomized, multicenter, open-label 
trial of intensive (target systolic blood pressure <120 mm Hg) 
versus standard blood pressure treatment (target systolic 
blood pressure <140 mm Hg) among adults with type 2 di-
abetes mellitus, conducted at 77 clinical sites in the United 
States and Canada between January 2003 and June 2009, 
with a mean follow-up of 4.7 years.11 Inclusion criteria for the 
ACCORD BP trial included age at least 40 years with cardio-
vascular disease or at least 55 years with anatomic evidence 
of substantial atherosclerosis, albuminuria, left ventricular hy-
pertrophy, or at least 2 additional cardiovascular disease risk 
factors (dyslipidemia, hypertension, smoking, or obesity); sys-
tolic blood pressure of 130 to 180 mm Hg taking ≤3 blood 
pressure agents and having a 24-hour protein excretion rate 
<1 g; and type 2 diabetes mellitus with a hemoglobin A1c 
level of at least 7.5%. Exclusion criteria included having a 
body mass index >45 kg/m2, serum creatinine >1.5 mg/dL, or 
other serious illness.11
The institutional review board at the University of North 
Carolina at Chapel Hill decided that approval was not re-
quired for this secondary analysis of deidentified data.
Outcomes
The primary outcome for the TOPCAT analysis in this study 
was the same as in the original TOPCAT trial—a composite 
outcome of death from cardiovascular causes, aborted car-
diac arrest, or hospitalization for the management of heart 
failure.2 The secondary outcome in this study was total (all-
cause) mortality.2
For the ACCORD BP analyses, we used the ACCORD BP 
primary outcome (a composite of nonfatal myocardial infarc-
tion, nonfatal stroke, and death from cardiovascular causes).11
Covariates
We considered an extensive set of covariates that may differ 
between study sites and thus may explain differences in the 
observed treatment-effect estimates. All data were taken from 
baseline data in the TOPCAT public data release, and details 
of their assessment and measures are provided in the study 
documentation. For our main TOPCAT analysis, we considered 
a set of variables that, based on prior literature regarding clin-
ical outcomes in individuals with heart failure with preserved 
ejection fraction, we hypothesized could be related to differ-
ences in observed outcomes across sites.12–14 These variables 
were age (years), sex, race/ethnicity (non-Hispanic white, 
non-Hispanic black, Hispanic, or Asian/multi/other), history 
of congestive heart failure hospitalization, history of implant-
able cardioverter defibrillator placement, use of angiotensin-
converting enzyme inhibitor or angiotensin receptor blocker, 
functional status as indicated by New York Heart Association 
heart failure class (I or II versus III or IV), systolic blood pressure, 
estimated glomerular filtration rate (using the modification of 
diet in renal disease equation), serum potassium level, study 
eligibility via hospitalization, and study eligibility via BNP value.
As robustness checks, we also considered an extended 
set of variables, described in the Appendix in the Data 
Supplement.
Variables used for modeling the outcome in the ACCORD 
BP analyses were study arm, age (years), sex, race/ethnicity 
(non-Hispanic white, non-Hispanic black, Hispanic, or Asian/
multi/other), educational attainment (categorized as less than 
high school diploma, high school diploma, some college, or 
college degree and higher), history of cardiovascular disease, 
years with diabetes mellitus, smoking status, body mass index, 
hemoglobin A1c level, systolic blood pressure, diastolic blood 
pressure, fasting plasma glucose, estimated glomerular filtra-
tion rate, urine albumin-to-creatinine ratio, total cholesterol, 
triglycerides, high-density lipoprotein cholesterol, low-den-
sity lipoprotein cholesterol, health insurance status, history 
of myocardial infarction, history of stroke, history of conges-
tive heart failure, and study glycemia treatment arm (because 
ACCORD was a factorial design in which participants were 
also randomized to intensive or standard glycemic control for 
type 2 diabetes mellitus).
Transportability Approach
We used a doubly robust, semiparametric targeted maxi-
mum-likelihood estimation (TMLE) transport estimator to pre-
dict the intent-to-treat effect in a target site, using data from 
both the target-site participants and a source-site treatment-
effect estimate.7,8,15 The approach models how participant 
covariates relate to the outcome in the source site and how 
covariates that may affect the outcome differ between the 
source and the target site. These models are then used to 
predict what results would be expected in the target site by 
standardizing the results of the source site over the covariate 
distribution in the target site (see conceptual illustration in 
Figure I in the Data Supplement). The mathematical details 
of the transported intent-to-treat estimated have been pub-
lished previously.7 We inferred study site from the participant’s 
country of residence. Because transport formulae for time-
to-event data have not yet been developed, we conducted 
our analyses using a dichotomous outcome (whether or not a 
person had the outcome by 36 months, with 36 months ap-
proximately being the median follow-up time) using logistic 
regression. Individuals who were censored before 36 months 
had their last outcome observation carried forward to 36 
months and were retained in the analysis. Before using this 
approach for estimating the transport equations, we checked 
whether this was a reasonable approximation. The logistic re-
gression analysis in TOPCAT data, with the primary outcome 
dichotomized at 36 months, produced an odds ratio of 0.86 
(95% CI, 0.71–1.03), which is similar to the estimate using 
Cox proportional hazards regression (hazard ratio, 0.89; 95% 
CI, 0.77–1.04) reported in the main TOPCAT analysis.2
For the ACCORD BP analyses, we similarly dichotomized 
the primary outcome (whether or not a person had the out-
come by 60 months, with 60 months being again approx-
imately the median follow-up time) and compared results 
from a logistic regression model to those of the Cox pro-
portional hazards model used as the primary analysis for the 
ACCORD BP study. The logistic regression model yielded an 
odds ratio of 0.87 (95% CI, 0.71–1.07), which was similar 
to the estimate from the Cox regression (hazard ratio, 0.88; 
95% CI, 0.73–1.07).
Assumptions of Transportability Methods
To estimate the expected intention-to-treat average treat-
ment effect in a target site using data from a source site, 3 
assumptions need to be met. The first assumption is that of a 
common outcome model. This can be expressed as E0 (Y|S=0, 
W, A)=E0 (Y|S=1, W, A). See Figure II in the Data Supplement 
for a graphical depiction of this. In words, this means that the 
mean value of the outcome (Y) in the source site (S=0) with 
its distribution of covariates (W) and treatment (A) would be 
the same as the mean value of the outcome at the target site 
(S=1) given the same covariates and treatment. The second 
assumption is that there are no unobserved confounders. This 
means that assignment of treatment (A) is independent of 
potential outcomes given observed covariates at the source 
site (S=0). Because both of the datasets analyzed in this study 
were randomized clinical trials, randomization provides this 
independence. Finally, the third assumption is positivity. This 
means that there is a nonzero probability of selection into 
a particular site and level of treatment given the observed 
covariates. In this study, the data are from randomized clinical 
trials, which helps ensure that, at least theoretically, all com-
binations of covariates included in the study have a nonzero 
chance at being assigned to a given treatment condition. In 
practice, however, rare combinations of covariates may not 
occur in all treatment levels.
Statistical Analysis
We first used data from the TOPCAT sites in the Americas and 
the TMLE transport estimator to generate an intent-to-treat 
estimate of expected study outcomes in the Russia/Georgia 
sites. These could then be compared against the observed 
outcomes at the Russia/Georgia sites. If the expected values 
were close to the observed outcomes, differences in observed 
patient characteristics could be responsible for the differences 
noted in Russia/Georgia treatment effects. If the expected 
values were different from the observed values, however, un-
observed factors, such as site protocol adherence or unmeas-
ured participant characteristics, could explain the differences 
in treatment effects.
Our analysis proceeded in 3 steps. First, we analyzed the 
data in the TOPCAT trial, stratified by site to generate the 
observed treatment-effect estimates by site. We expressed 
these values as cumulative incidence of the primary and of 
the secondary outcome at 36 months and the difference be-
tween study arms as risk differences at 36 months. We also 
replicated the Cox proportional hazard regression analysis 
conducted in the main trial analysis, adding an interaction 
term to determine whether site-level differences in treatment 
effect would have been detected using this approach. Finally, 
we used logistic regression analyses, adjusted for the same 
covariates as in the transport analyses, to test a site-by-treat-
ment interaction term to determine whether this approach 
could detect site-level differences.
Next, we applied the TMLE transport estimator to gen-
erate estimates of the expected results, based on the distribu-
tion of covariates in study participants in the Russia/Georgia 
sites of TOPCAT. In addition to conducting robustness checks 
using additional variables in the TMLE transport equations, 
we also conducted a robustness check adjusting for follow-up 
time because our approach required the use of logistic regres-
sion rather than a time-to-event analysis.
Finally, we assessed the differences between observed and 
expected values for the outcome using calibration metrics 
(analogous to the comparison of observed and expected values 
for risk prediction models). We specifically applied the Hosmer-
Lemeshow test,16 which tests whether the observed event rates 
match the expected event rates by deciles of expected rates. 
We additionally applied the calibration belt approach proposed 
by Nattino et al17 (the Italian Group for the Evaluation of the 
Interventions in Intensive Care Units [GiViTI] calibration test), 
which derives confidence bands around a polynomial fit be-
tween the expected and observed outcome rates.18 For both 
the Hosmer-Lemeshow and GiViTI calibration test, the null hy-
pothesis is that the model is well calibrated, so lower P values 
suggest a more significant difference between expected and 
observed values (more indication of site variations, rather than 
observed population variations, as explanations for treatment-
effect heterogeneity between sites). In addition to testing the 
overall goodness of fit, we explored the stratified goodness of 
fit in the placebo groups and spironolactone groups individual. 
This would allow us to determine whether any discrepancies 
occurred in either or both arms of the trial.
In this study, we used the standard P<0.05 threshold 
to indicate statistical significance (and thus miscalibration 
between observed and expected event rates), but we be-
lieve it is worth noting that other thresholds may be use-
ful. Particularly as our approach may be used to flag trial 
sites that need further investigation, rather than to definitely 
establish a discrepancy, using a higher threshold would in-
crease sensitivity for detecting aberrations at the expense of 
decreasing specificity, which some data monitoring boards 
may desire. To that end, we estimated 80% CIs along with 
95% CIs on calibration plots.
Falsification Testing
To test whether the methodology may be overly sensitive, 
identifying even slight and inconsequential variations across 
sites as being important for investigation, we repeated our 
analyses using a trial where no clinically meaningful differ-
ences across sites were expected based on prior monitoring: 
the ACCORD BP trial.
We selected ACCORD BP as a comparator trial because 
it had an approximately similar, but slightly larger number of 
participants, than TOPCAT (4733 in ACCORD BP versus 3445 
in TOPCAT), such that ACCORD BP transport results should 
be more sensitive to minor deviations, and we would be mod-
eling cardiovascular outcomes where the risk factors for the 
trial outcomes are thought to be well understood. We ran-
domly selected 3 of the 7 clinical networks used in ACCORD 
BP to serve as the transport sites, with the remaining 4 serving 
as the source sites. The 3 selected sites represented a sim-
ilar proportion of participants in ACCORD BP as the Russia/
Georgia sites did in TOPCAT.
In the main analyses, 3434 of 3445 (99.7%) participants had 
complete data, so no imputation was used. In the first set of ro-
bustness checks, 3411 of 3445 (99.0%) had complete data, so 
we also did not use imputation. In the second set of robustness 
checks, 2827 of 3445 (82.1%) had complete data, owing to 
18% missingness for the physical activity variable. Therefore, 
for the third set of robustness checks, we conducted both com-
plete-case analyses and analyses using a nonparametric impu-
tation method based on a random forest, called missForest.19,20 
For the ACCORD BP analysis, 4507 of 4733 (95.2%) observa-
tions had complete data, so no imputation was used.
Analyses were conducted in SAS, version 9.4 (SAS 
Institute, Cary, NC), and R, version 3.4.2 (R Foundation for 
Statistical Computing, Vienna, Austria). TOPCAT and 
ACCORD data are available from the National Heart, 
Lung, and Blood Institute Biologic Specimen and Data 
Repository Information Coordinating Center (https://
biolincc.nhlbi.nih.gov/home/) under a data use agreement 
but cannot be shared by the authors. Statistical code for 
the transportability analyses was adapted from Rudolph 
and van der Laan7 and will be avail-able, at time of 
publication, from the authors’ website.21
differences between the samples at the Russia/Georgia 
site versus the other site. Participants at the Russia/Geor-
gia site were younger, more commonly of non-Hispanic 
white race, had higher prevalence of previous heart fail-
ure hospitalization, had higher baseline systolic blood 
pressure, and had better baseline renal function.
Primary and Secondary Outcomes Across 
Study Sites
Across all TOPCAT sites, 16.8% of individuals in the 
placebo group and 14.8% of individuals in the spiro-
nolactone group experienced the primary outcome by 
36 months. At the Russia/Georgia sites, 6.4% of the 
placebo group and 6.5% of the spironolactone group 
experienced the primary outcome; at the other sites, 
26.8% of the placebo group and 22.6% of the spiro-
nolactone group experienced the primary outcome. A 
similar discrepancy was present for the secondary out-
come of total mortality (Table 2).
RESULTS
Characteristics of the Participant Sample 
From TOPCAT
The demographic and clinical characteristics of partici-
pants in TOPCAT, both overall and stratified by site (Rus-
sia/Georgia versus all other sites) are presented in Table 1 
and an extended set of demographics in Table I in the 
Data Supplement. Overall, there were many significant 
Table 1. Demographics Overall and by Study Site
Overall
Russia/
Georgia Site Other Countries
P Value
n=3445 n=1678 n=1767
Mean (SD) or n (%) Mean (SD) or n (%) Mean (SD) or n (%)
Age at study entry, y 68.56 (9.59) 65.44 (8.42) 71.52 (9.69) <0.001
Women 1775 (51.5) 893 (53.2) 882 (49.9) 0.057
Race/ethnicity <0.001
 Non-Hispanic white 2824 (82.0) 1675 (99.8) 1149 (65.0)
 Non-Hispanic black 269 (7.8) 0 (0.0) 269 (15.2)
 Hispanic 321 (9.3) 3 (0.2) 318 (18.0)
 Asian/multi/other 31 (0.9) 0 (0.0) 31 (1.8)
Country NA
 United States 1151 (33.4) 0 (0.0) 1151 (65.1)
 Canada 326 (9.5) 0 (0.0) 326 (18.4)
 Russia 1066 (30.9) 1066 (63.5) 0 (0.0)
 Republic of Georgia 612 (17.8) 612 (36.5) 0 (0.0)
 Brazil 167 (4.8) 0 (0.0) 167 (9.5)
 Argentina 123 (3.6) 0 (0.0) 123 (7.0)
Assigned to spironolactone 1722 (50.0) 836 (49.8) 886 (50.1) 0.878
History of CHF hospitalization 2489 (72.3) 1449 (86.4) 1040 (58.9) <0.001
History of ICD placement 44 (1.3) 2 (0.1) 42 (2.4) <0.001
Systolic blood pressure 129.22 (13.97) 131.00 (11.37) 127.52 (15.87) <0.001
NYHA class III or IV heart failure at baseline 1136 (33.0) 516 (30.8) 620 (35.2) 0.007
Use of ACE inhibitor/ARB 2900 (84.3) 1505 (89.7) 1395 (79.0) <0.001
Estimated glomerular filtration rate, mL/min 67.67 (20.15) 71.03 (18.03) 64.47 (21.50) <0.001
Serum potassium, mmol/L 4.25 (0.45) 4.32 (0.45) 4.19 (0.43) <0.001
Met hospitalization inclusion criterion 2464 (71.5) 1488 (88.7) 976 (55.2) <0.001
Met BNP inclusion criterion 1444 (41.9) 306 (18.2) 1138 (64.4) <0.001
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BNP, brain natriuretic peptide; CHF, congestive heart 
failure; ICD, implantable cardioverter defibrillator; and NYHA, New York Heart Association.
Standard Analysis
To investigate whether a discrepancy across sites could 
have been found using a standard statistical approach, 
we fit a Cox proportional hazards regression (the anal-
ysis strategy specified in the trial protocol) with terms 
for site (Russia/Georgia versus the Americas), treatment 
(spironolactone versus placebo), and site-by-treatment 
interaction. The interaction term was not significant in 
the analysis of either the primary outcome (P=0.12) or 
total mortality (P=0.20), indicating that this approach 
did not detect differences across sites. In addition, we 
conducted a logistic regression analysis, adjusting for 
the same factors used in the transport analysis, to test 
a site-by-treatment interaction term. This interaction 
term was not significant when analyzing either the pri-
mary outcome (P=0.17) or total mortality (P=0.42) ei-
ther, indicating that this approach also did not detect 
differences across sites.
Transport Analysis
TMLE transport analyses revealed that expected rates for 
the primary and secondary outcome, based on the dem-
ographic and clinical characteristics of the participants, 
were actually higher in the Russia/Georgia sites than the 
other sites (Table 2). For example, we would have ex-
pected 26.8% of individuals in the placebo group in the 
Russia/Georgia site to have experienced the primary out-
come, based on their demographic and clinical charac-
teristics, instead of the 6.4% who actually did, suggest-
ing that observed participant characteristics included in 
our model were unlikely to explain the Russia/Georgia 
treatment-effect results. Goodness-of-fit testing showed 
that the expected values did not match those observed 
(Hosmer-Lemeshow test P <0.001 and GiViTI calibration 
test statistic <0.001 for both the primary outcome and 
total mortality). As Figures 1 and 2 show, expected out-
come rates were significantly greater than observed out-
come rates across all levels of cardiovascular event risk 
for both outcomes. In robustness checks adjusting for 
follow-up time, using additional covariates, or imputing 
missing values, the Hosmer-Lemeshow test and GiViTI 
calibration test P strongly indicated lack of fit in all cases, 
supporting our finding that the Russia/Georgia partic-
ipant characteristics did not explain the heterogeneity 
in those sites’ observations (and was instead poten-
tially because of protocol violations) across the different 
specifications (Table II in the Data Supplement; Figures III 
through VI in the Data Supplement).
Finally, we explored whether the lack of fit between 
observed and expected values in the Russia/Georgia 
sites of TOPCAT occurred in the placebo group, spi-
ronolactone group, or both. We did this by conducting 
goodness-of-fit testing stratified by treatment group. We 
found that there was a lack of fit for both the placebo 
and spironolactone groups (Table III in the Data Supple-
ment; Figures VII through X in the Data Supplement).
Falsification Testing
In falsification testing, there were differences across 
sites in ACCORD BP regarding a number of factors—
notably race/ethnicity, education, history of cardiovas-
cular disease, and hemoglobin A1c (Table IV in the Data 
Supplement). Despite this, however, we found that 
the observed outcomes matched the expected derived 
using the transport method (Hosmer-Lemeshow test, 
P=0.21; GiViTI calibration test, P=0.17; Figure XI in the 
Data Supplement), meaning that site differences could 
largely be explained by participant characteristic varia-
tions (Table 3).
DISCUSSION
In this study, we found that transport analyses detected 
anomalies in the Russia/Georgia sites of the TOPCAT 
Table 2. Observed and Expected Incidence of Primary Outcome and Total Mortality at 36 mo in TOPCAT
Observed Expected











 Placebo 290 (16.83) … 192 (11.14) … … …
 Spironolactone 254 (14.75) −2.1% 164 (9.52) −1.6% … …
Russian/Georgian sites
 Placebo 54 (6.41) … 46 (5.46) … 225 (26.8) … 123 (14.63) …
 Spironolactone 54 (6.46) 0.05% 42 (5.02) −0.4% 134 (16.0) −10.7% 77 (9.21) −5.4%
All other sites
 Placebo 236 (26.79) … 146 (16.57) … … …
 Spironolactone 200 (22.57) −4.2% 122 (13.77) −2.8% … …
TOPCAT indicates Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist.
study—specifically that observed participant character-
istics did not explain differences in the treatment effects 
observed between the Russia/Georgia sites and sites in 
the Americas. Standard site-by-treatment interaction test-
ing did not detect these differences. The transportability 
method did not appear overly sensitive to site variations 
when additionally tested in the ACCORD BP trial, where 
the methods suggested that between-site variations were 
attributable to differences in participant characteristics.
The transportability method adds important insights 
to the existing literature on the conduct of large multi-
center trials. First, it offers the opportunity to contextu-
alize and evaluate whether heterogeneity in treatment 
effects may be because of important observed partici-
pant characteristics that may modify the impact of ther-
apy and, therefore, would be important for practitioners 
generalizing the results of a trial to their patient popula-
tions. Second, it offers a warning flag for post hoc eval-
uation of a trial where study sites may substantially differ 
in effect size estimates for reasons other than observed 
participant characteristics. The availability of such meth-
ods, coupled with the increased sharing of clinical trial 
data, may assist trialists who have identified that man-
agement and monitoring of international multisite trials 
is particularly important but challenging.1,3–5 Third, the 
method can quantify whether the observed treatment 
effects are larger or smaller than the expected effects 
adjusted for population characteristics, which may help 
identify the direction and magnitude of the problem.
Figure 1. Calibration plot for primary outcome in the TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone An-
tagonist) Russia/Georgia sites.  
A comparison of transported predicted primary outcome rates at Russia/Georgia sites based on results from other sites, vs observed outcomes in the TOPCAT trial. 
The diagonal bisecting line represents where observed equals expected outcome rates at every risk level and thus where the participant characteristics would be 
expected to explain heterogeneity in treatment effects between sites rather than site-specific anomalies in study protocol or other unobserved factors influencing 
the results. Light gray bands indicate the 80% confidence region, and darker gray bands represent the region of 95% confidence. Areas below the bisecting line 
indicate that predicted risk was higher than observed and vice versa. Inset chart shows the specific levels of predicted risk and whether they were over or under 
the bisecting line. Probability levels not in chart (eg, <0.05 or >0.57) were not present in this study and thus are not plotted. TMLE indicates targeted maximum-
likelihood estimation.
Table 3. Observed and Expected Incidence of Primary Outcome and 
Total Mortality at 36 mo in TOPCAT
Observed Expected







 Standard control 209 (8.81) … …
 Intensive control 185 (7.83) −0.98 …
Transport sites
 Standard control 71 (7.40) … 85 (9.00) …
 Intensive control 73 (7.73) 0.33 80 (8.31) −0.66
Source sites
 Standard control 138 (9.77) … …
 Intensive control 112 (7.90) −1.87 …
Randomly selected transport sites were networks 1, 2, and 3 (further 
characterization is not provided in publicly available data to preserve participant 
anonymity). Source sites were networks 4 to 7. TOPCAT indicates Treatment of 
Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist.
Nevertheless, there are important limitations to the 
approach. Most importantly, transportability of a re-
sult from one site to other depends on the choice of 
participant covariates to standardize against and thus 
can only incorporate observed patient features. Clini-
cal trials may not measure all relevant characteristics, 
and so important factors that influence the treatment 
effect may be unmeasured. In this case, site variations 
could lead to suspicions that sites did not follow pro-
tocols, when in fact unknown or unmeasured factors 
caused the site’s population to be systematically differ-
ent from the sample at other sites. Therefore, variations 
detected by transportability methods should serve only 
as a prompt for further investigation. Further, using the 
transportability methods in this way assumes that the 
relationship between baseline characteristics and the 
treatment on the outcome is similar enough across sites 
to be able to use the relationship at one site to predict 
the outcomes of another site. A multisite trial inherently 
makes a different, potentially stronger assumption—
that there is a common overall treatment effect on the 
outcome (independent of covariates) across sites—or 
else one could not meaningfully pool the results to es-
timate a single average treatment effect of the inter-
vention in the trial. If this assumption does not hold, 
then the differences in this relationship may explain 
any variation in outcomes observed. Second, our test 
here applied the method to only 2 trials. More subtle 
and smaller sample trials may need to be considered 
in the future to identify transportability method limita-
tions. Third, the evidence presented here was to help 
post hoc trial analyses when heterogeneity in treat-
ment effects across sites is observed or suspected. The 
results do not provide clear guidance for researchers 
performing interim analysis as part of the data monitor-
ing team, which presents the difficulty of both false-
positive findings and statistical power. A future analysis 
using simulations would be appropriate to decipher the 
power of traditional and novel transportability methods 
to determine the degree to which the method should 
be applied to interim monitoring exercises. Finally, be-
cause of the novelty of transportability methods, we 
used a dichotomous (as opposed to time-to-event anal-
ysis) outcome analysis strategy.
Given the ubiquity of multisite trials, the significant 
resources invested in them, and the tendency to prefer 
results from randomized trials over other study designs, 
confidence in trial results is of the utmost importance. 
The movement toward making individual patient data 
available, when coupled with innovative analytic tech-
niques, such as transportability methods, may be an im-
portant way to increase our confidence in the results of 
Figure 2. Calibration plot of total mortality in the TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antago-
nist) Russia/Georgia sites.  
A comparison of transported predicted primary outcome rates at Russia/Georgia sites based on results from other sites, vs observed outcomes in the TOPCAT trial. The 
diagonal bisecting line represents where observed equals expected outcome rates at every risk level and thus where the participant characteristics would be expected 
to explain heterogeneity in treatment effects between sites rather than site-specific anomalies in study protocol or other unobserved factors influencing the results. 
Light gray bands indicate the 80% confidence region, and darker gray bands represent the region of 95% confidence. Areas below the bisecting line indicate that 
predicted risk was higher than observed and vice versa. Inset chart shows the specific levels of predicted risk and whether they were over or under the bisecting line. 
Probability levels not in chart (eg, <0.04 or >0.38) were not present in this study and thus are not plotted. TMLE indicates targeted maximum-likelihood estimation.
randomized trials and ultimately improve patient care by 
basing our treatments on the best available evidence.
ARTICLE INFORMATION
Received May 21, 2018; accepted January 16, 2019.
The Data Supplement is available at https://www.ahajournals.org/doi/suppl/ 
10.1161/CIRCOUTCOMES.118.004907.
Correspondence
Seth A. Berkowitz, MD, MPH, Division of General Medicine and Clinical Epi-
demiology, Department of Medicine, University of North Carolina School of 
Medicine, 5034 Old Clinic Bldg, CB 7110, Chapel Hill, NC 27599. Email seth_
berkowitz@med.unc.edu
Affiliations
Division of General Medicine and Clinical Epidemiology, Department of Medi-
cine, University of North Carolina School of Medicine, Chapel Hill (S.A.B.). Cecil 
G. Sheps Center for Health Services Research, University of North Carolina at
Chapel Hill (S.A.B.). Department of Emergency Medicine, School of Medicine,
University of California, Davis, Sacramento (K.E.R.). Center for Primary Care
and Outcomes Research (S.B.), Center for Population Health Sciences (S.B.),
Department of Medicine (S.B.), and Department of Health Research and Pol-
icy (S.B.), Stanford University, CA. Center for Primary Care, Harvard Medical
School, Boston, MA (S.B.).
Acknowledgments
This article was prepared using TOPCAT (Treatment of Preserved Cardiac Func-
tion Heart Failure With an Aldosterone Antagonist) and ACCORD (Action to 
Control Cardiovascular Risk in Diabetes) research materials obtained from the 
National Heart, Lung, and Blood Institute (NHLBI) Biologic Specimen and Data 
Repository Information Coordinating Center and does not necessarily reflect 
the opinion or views of the ACCORD or TOPCAT studies or the NHLBI. We also 
thank 2 anonymous reviewers for helpful comments incorporated into the ar-
ticle. Dr Berkowitz had full access to all of the data in the study and takes full 
responsibility for the work as a whole, including the study design, access to 
data, the integrity of the data, the accuracy of the data analysis, and the deci-
sion to submit and publish the manuscript. All authors had access to the data 
and agree to submission of the manuscript for publication. Dr Berkowitz affirms 
that the manuscript is an honest, accurate, and transparent account of the 
study being reported; that no important aspects of the study have been omit-
ted; and that there are no discrepancies from the study as originally planned. 
Dr Basu conceived the study and revised the manuscript for critical intellectual 
content. Dr Berkowitz made significant contributions to the design of the study, 
conducted analysis of the data, and drafted the manuscript. Dr Rudolph made 
significant intellectual contributions to the design of the study and revised the 
manuscript for critical intellectual content.
Sources of Funding
Research reported in this publication was supported by the National Institute 
for Diabetes and Digestive and Kidney Disease of the National Institutes of 
Health, the National Institute on Minority Health and Health Disparities, and 
the National Institute on Drug Abuse of the National Institutes of Health un-
der award numbers DP2MD010478 (Dr Basu), U54MD010724 (Dr Basu), 
K23DK109200 (Dr Berkowitz), and R00DA042127 (Dr Rudolph). The content 
is solely the responsibility of the authors and does not necessarily represent the 
official views of the National Institutes of Health. The funders had no role in the 
study design; in the collection, analysis, and interpretation of data; in the writ-




1. Bristow MR, Enciso JS, Gersh BJ, Grady C, Rice MM, Singh S, Sopko G,
Boineau R, Rosenberg Y, Greenberg BH. Detection and management
of geographic disparities in the TOPCAT trial: lessons learned and de-
rivative recommendations. JACC Basic Transl Sci. 2016;1:180–189. doi: 
10.1016/j.jacbts.2016.03.001
2. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell 
N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood
CT, Lewis EF, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon
SD, Sweitzer NK, Yang S, McKinlay SM; TOPCAT Investigators. Spirono-
lactone for heart failure with preserved ejection fraction. N Engl J Med. 
2014;370:1383–1392. doi: 10.1056/NEJMoa1313731
3. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N,
Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O’Meara E, Rou-
leau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer
NK, McKinlay SM, Pitt B. Regional variation in patients and outcomes in
the Treatment of Preserved Cardiac Function Heart Failure With an Al-
dosterone Antagonist (TOPCAT) trial. Circulation. 2015;131:34–42. doi:
10.1161/CIRCULATIONAHA.114.013255
4. de Denus S, O’Meara E, Desai AS, Claggett B, Lewis EF, Leclair G, Jutras
M, Lavoie J, Solomon SD, Pitt B, Pfeffer MA, Rouleau JL. Spironolactone
metabolites in TOPCAT - new insights into regional variation. N Engl J
Med. 2017;376:1690–1692. doi: 10.1056/NEJMc1612601
5. George SL, Buyse M. Data fraud in clinical trials. Clin Investig (Lond). 
2015;5:161–173. doi: 10.4155/cli.14.116
6. The International Conference on Harmonisation of Technical Require-
ments for Registration of Pharmaceuticals for Human Use. General Prin-
ciples for Planning and Design of Multi-Regional Clinical Trials [Internet].
2017. [cited April 19, 2018]. http://www.ich.org/fileadmin/Public_Web_
Site/ICH_Products/Guidelines/Efficacy/E17/E17EWG_Step4_2017_1116.
pdf. Accessed April 19, 2018.
7. Rudolph KE, van der Laan MJ. Robust estimation of encouragement-de-
sign intervention effects transported across sites. J R Stat Soc Series B Stat 
Methodol. 2017;79:1509–1525. doi: 10.1111/rssb.12213
8. Rudolph KE, Schmidt NM, Glymour MM, Crowder R, Galin J, Ahern J,
Osypuk TL. Composition or context: using transportability to understand
drivers of site differences in a large-scale housing experiment. Epidemiol-
ogy. 2018;29:199–206. doi: 10.1097/EDE.0000000000000774
9. Bareinboim E, Pearl J. Causal inference and the data-fusion problem. Proc 
Natl Acad Sci U S A. 2016;113:7345–7352. doi: 10.1073/pnas.1510507113
10. Westreich D, Edwards JK, Lesko CR, Stuart E, Cole SR. Transportability
of trial results using inverse odds of sampling weights. Am J Epidemiol. 
2017;186:1010–1014. doi: 10.1093/aje/kwx164
11. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC
Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA,
Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT,
Gerstein HC, Ismail-Beigi F. Effects of intensive blood-pressure control
in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–1585. doi:
10.1056/NEJMoa1001286
12. Udelson JE. Heart failure with preserved ejection fraction. Circulation. 
2011;124:e540–e543. doi: 10.1161/CIRCULATIONAHA.111.071696
13. Redfield MM. Heart failure with preserved ejection fraction. N Engl J Med. 
2016;375:1868–1877. doi: 10.1056/NEJMcp1511175
14. Zakeri R, Cowie MR. Heart failure with preserved ejection fraction: contro-
versies, challenges and future directions. Heart. 2018;104:377–384. doi:
10.1136/heartjnl-2016-310790
15. Luedtke AR, Carone M, van der Laan MJ. An omnibus nonparametric test 
of equality in distribution for unknown functions. ArXiv.org. 2015. http://
arxiv.org/abs/1510.04195. Accessed May 1, 2018.
 16. Hosmer DW, Lemeshow S. Assessing the fit of the model. In: Ap-
plied Logistic Regression. Hoboken, NJ: John Wiley & Sons, Inc; 2005
[cited April 19, 2018]:143–202. Available from: http://doi.wiley.
com/10.1002/0471722146.ch5.
17. Nattino G, Finazzi S, Bertolini G. A new calibration test and a reappraisal of 
the calibration belt for the assessment of prediction models based on dichot-
omous outcomes. Stat Med. 2014;33:2390–2407. doi: 10.1002/sim.6100
18. Finazzi S, Poole D, Luciani D, Cogo PE, Bertolini G. Calibration belt for
quality-of-care assessment based on dichotomous outcomes. PLoS One. 
2011;6:e16110. doi: 10.1371/journal.pone.0016110
19. Shah AD, Bartlett JW, Carpenter J, Nicholas O, Hemingway H. Comparison 
of random forest and parametric imputation models for imputing missing 
data using MICE: a CALIBER study. Am J Epidemiol. 2014;179:764–774.
doi: 10.1093/aje/kwt312
20. Stekhoven DJ, Bühlmann P. MissForest–non-parametric missing value
imputation for mixed-type data. Bioinformatics. 2012;28:112–118. doi:
10.1093/bioinformatics/btr597
21. Berkowitz SA. Statistical Code. https://saberkowitz.web.unc.edu/statisti-
cal-code/tmle-transport-code/. Accessed January 21, 2019.
